Advertisement

Lasers in Medical Science

, Volume 34, Issue 3, pp 473–478 | Cite as

AMPH-1 is a tumor suppressor of lung cancer by inhibiting Ras-Raf-MEK-ERK signal pathway

  • Haifeng YangEmail author
  • Zhenzhou Wan
  • Cheng Huang
  • Huabin Yin
  • Dianwen Song
Original Article
  • 115 Downloads

Abstract

Amphiphysin 1 (AMPH-1) is a nerve terminal-enriched protein and it is a 128-kD protein with three identified functional domains. Some studies found that AMPH-1 was a dominant autoantigen associated with breast cancer and melanoma. However, its function in lung cancer is unknown. Here, we showed that AMPH-1 knockdown dramatically increased cell proliferation, attenuated cell apoptosis, and promoted cell cycle progression in human lung cancer cells. In vivo xenograft studies confirmed that the AMPH-1-knockdown cells were more tumorigenic than the controls. Moreover, we demonstrated that silencing AMPH-1 markedly activated Ras-Raf-MEK-ERK signal pathway. In summary, our results identified the anti-oncogenic function of AMPH-1 in lung cancer in vitro and in vivo. It is proposed that AMPH-1 may have potential as a new therapeutic target in human lung cancer treatment.

Keywords

AmphiphysinApoptosis Tumorigenic Ras-Raf-MEK-ERK signal pathway 

Notes

Role of funding source

This work was sponsored by Qing Lan Project in Jiangsu Province of China. This work was also supported by the National Natural Science Foundation of China (No.81772856, 81,402,222) and Youth Fund of Shanghai Municipal Health Planning Commission (No.2017YQ054, 2017Y0117).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All experimental protocols and methods were approved by the Jiangsu Agri-Animal Husbandry Vocational College. We also confirmed that all methods were performed in accordance with the relevant guidelines and regulations. Mice were bred in the Animal Core Facility by following procedures approved by the Jiangsu Agri-Animal Husbandry Vocational College of Institutional Animal Care and Use Committee.

References

  1. 1.
    Sharma SV, Bell DW, Settleman J, Haber DA (2007) Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169–181CrossRefGoogle Scholar
  2. 2.
    Brambilla E, Travis WD, Colby TV, Corrin B, Shimosato Y (2001) The new World Health Organization classification of lung tumours. Eur Respir J 18:1059–1068CrossRefGoogle Scholar
  3. 3.
    Mills NE, Fishman CL, Rom WN, Dubin N, Jacobson DR (1995) Increased prevalence of K-ras oncogene mutations in lung adenocarcinoma. Cancer Res 55:1444–1447Google Scholar
  4. 4.
    Reynolds SH, Anna CK, Brown KC et al (1991) Activated protooncogenes in human lung tumors from smokers. Proc Natl Acad Sci U S A 88:1085–1089CrossRefGoogle Scholar
  5. 5.
    Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF (1991) Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 6:1353–1362Google Scholar
  6. 6.
    Fisher GH, Wellen SL, Klimstra D et al (2001) Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev 15:3249–3262CrossRefGoogle Scholar
  7. 7.
    Guerra C, Mijimolle N, Dhawahir A et al (2003) Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4:111–120CrossRefGoogle Scholar
  8. 8.
    Jackson EL, Willis N, Mercer K et al (2001) Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev 15:3243–3248CrossRefGoogle Scholar
  9. 9.
    Ji H, Houghton AM, Mariani TJ et al (2006) K-ras activation generates an inflammatory response in lung tumors. Oncogene 25:2105–2112CrossRefGoogle Scholar
  10. 10.
    Johnson L, Mercer K, Greenbaum D et al (2001) Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 410:1111–1116CrossRefGoogle Scholar
  11. 11.
    Farago AF, Snyder EL, Jacks T (2012) SnapShot: lung cancer models. Cell 149:246–246 e241CrossRefGoogle Scholar
  12. 12.
    Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA (2008) Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:584–594CrossRefGoogle Scholar
  13. 13.
    Mehlen P, Puisieux A (2006) Metastasis: a question of life or death. Nat Rev Cancer 6:449–458CrossRefGoogle Scholar
  14. 14.
    Mitsuuchi Y, Testa JR (2002) Cytogenetics and molecular genetics of lung cancer. Am J Med Genet 115:183–188CrossRefGoogle Scholar
  15. 15.
    Ding L, Getz G, Wheeler DA et al (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455:1069–1075CrossRefGoogle Scholar
  16. 16.
    Weir BA, Woo MS, Getz G et al (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:893–898CrossRefGoogle Scholar
  17. 17.
    Pittock SJ, Lucchinetti CF, Parisi JE et al (2005) Amphiphysin autoimmunity: paraneoplastic accompaniments. Ann Neurol 58:96–107CrossRefGoogle Scholar
  18. 18.
    David C, McPherson PS, Mundigl O, de Camilli P (1996) A role of amphiphysin in synaptic vesicle endocytosis suggested by its binding to dynamin in nerve terminals. Proc Natl Acad Sci U S A 93:331–335CrossRefGoogle Scholar
  19. 19.
    Wigge P, Kohler K, Vallis Y et al (1997) Amphiphysin heterodimers: potential role in clathrin-mediated endocytosis. Mol Biol Cell 8:2003–2015CrossRefGoogle Scholar
  20. 20.
    Slepnev VI, Ochoa GC, Butler MH, De Camilli P (2000) Tandem arrangement of the clathrin and AP-2 binding domains in amphiphysin 1 and disruption of clathrin coat function by amphiphysin fragments comprising these sites. J Biol Chem 275:17583–17589CrossRefGoogle Scholar
  21. 21.
    De Jesus-Cortes HJ, Nogueras-Ortiz CJ, Gearing M, Arnold SE, Vega IE (2012) Amphiphysin-1 protein level changes associated with tau-mediated neurodegeneration. Neuroreport 23:942–946CrossRefGoogle Scholar
  22. 22.
    Sekiguchi M, Katayama S, Hatano N, Shigeri Y, Sueyoshi N, Kameshita I (2013) Identification of amphiphysin 1 as an endogenous substrate for CDKL5, a protein kinase associated with X-linked neurodevelopmental disorder. Arch Biochem Biophys 535:257–267CrossRefGoogle Scholar
  23. 23.
    Floyd SR, Porro EB, Slepnev VI, Ochoa GC, Tsai LH, De Camilli P (2001) Amphiphysin 1 binds the cyclin-dependent kinase (cdk) 5 regulatory subunit p35 and is phosphorylated by cdk5 and cdc2. J Biol Chem 276:8104–8110CrossRefGoogle Scholar
  24. 24.
    Wu Y, Matsui H, Tomizawa K (2009) Amphiphysin I and regulation of synaptic vesicle endocytosis. Acta Med Okayama 63:305–323Google Scholar
  25. 25.
    Takei K, Slepnev VI, Haucke V, De Camilli P (1999) Functional partnership between amphiphysin and dynamin in clathrin-mediated endocytosis. Nat Cell Biol 1:33–39CrossRefGoogle Scholar
  26. 26.
    Folli F, Solimena M, Cofiell R et al (1993) Autoantibodies to a 128-kd synaptic protein in three women with the stiff-man syndrome and breast cancer. N Engl J Med 328:546–551CrossRefGoogle Scholar
  27. 27.
    De Camilli P, Thomas A, Cofiell R et al (1993) The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of Stiff-Man syndrome with breast cancer. J Exp Med 178:2219–2223CrossRefGoogle Scholar
  28. 28.
    Schmierer K, Grosse P, De Camilli P, Solimena M, Floyd S, Zschenderlein R (2002) Paraneoplastic stiff-person syndrome: no tumor progression over 5 years. Neurology 58:148CrossRefGoogle Scholar
  29. 29.
    Crouzet M, Urdaci M, Dulau L, Aigle M (1991) Yeast mutant affected for viability upon nutrient starvation: characterization and cloning of the RVS161 gene. Yeast 7:727–743CrossRefGoogle Scholar
  30. 30.
    Bauer F, Urdaci M, Aigle M, Crouzet M (1993) Alteration of a yeast SH3 protein leads to conditional viability with defects in cytoskeletal and budding patterns. Mol Cell Biol 13:5070–5084CrossRefGoogle Scholar
  31. 31.
    Dropcho EJ (1996) Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 39:659–667CrossRefGoogle Scholar
  32. 32.
    Dalmau J, Graus F, Rosenblum MK, Posner JB (1992) Anti-Hu-associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71:59–72CrossRefGoogle Scholar
  33. 33.
    Otsuka A, Hirose K, Kilimann MW, Kamata T (2003) Amphiphysin1 inhibits vitronectin-mediated cell adhesion, spreading, and migration in vitro. Biochem Biophys Res Commun 301:769–775CrossRefGoogle Scholar
  34. 34.
    Karreth FA, Frese KK, DeNicola GM, Baccarini M, Tuveson DA (2011) C-Raf is required for the initiation of lung cancer by K-Ras (G12D). Cancer Discov 1:128–136CrossRefGoogle Scholar
  35. 35.
    Janku F, Lee JJ, Tsimberidou AM et al (2011) PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS One 6:e22769CrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Ltd., part of Springer Nature 2018

Authors and Affiliations

  • Haifeng Yang
    • 1
    Email author
  • Zhenzhou Wan
    • 2
  • Cheng Huang
    • 1
  • Huabin Yin
    • 3
  • Dianwen Song
    • 3
  1. 1.Jiangsu Agri-Animal Husbandry Vocational CollegeTaizhouPeople’s Republic of China
  2. 2.Medical Laboratory of Taizhou Fourth People’s HospitalTaizhouChina
  3. 3.Department of Orthopedics, Shanghai General Hospital, School of MedicineShanghai Jiaotong UniversityShanghaiPeople’s Republic of China

Personalised recommendations